Transient TKI-resistant CD44+pBAD+ blasts undergo intrinsic homeostatic adaptation to promote the survival of acute myeloid leukemia in vitro

Acute myeloid leukemia (AML) patients have frequent mutations in FMS-like receptor tyrosine kinase 3 (FLT3-mut AML), who respond poorly to salvage chemotherapies and targeted therapies such as tyrosine kinase inhibitors (TKIs). Disease relapse is a common reason of treatment failures in FLT3-mut AML...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Yi Xu, David J. Baylink, Chien-Shing Chen, Laren Tan, Jeffrey Xiao, Brandon Park, Ismael Valladares, Mark E. Reeves, Huynh Cao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Subjects:	AML tyrosine kinase inhibitor compensation CD44 JAK/STAT BAD
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1286863/full